TG Therapeutics Inc Expected to Earn FY2020 Earnings of ($1.71) Per Share (TGTX)

Share on StockTwits

TG Therapeutics Inc (NASDAQ:TGTX) – Equities research analysts at SunTrust Banks dropped their FY2020 earnings per share estimates for TG Therapeutics in a research note issued on Monday, April 1st. SunTrust Banks analyst P. Lawson now forecasts that the biopharmaceutical company will post earnings of ($1.71) per share for the year, down from their prior forecast of ($1.69). SunTrust Banks also issued estimates for TG Therapeutics’ FY2021 earnings at ($1.59) EPS and FY2022 earnings at ($0.40) EPS.

TGTX has been the subject of a number of other reports. BidaskClub downgraded TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, January 17th. Jefferies Financial Group restated a “buy” rating and issued a $8.00 price target on shares of TG Therapeutics in a research report on Wednesday, February 6th. B. Riley started coverage on TG Therapeutics in a research report on Tuesday, January 8th. They issued a “buy” rating and a $10.00 price target for the company. Zacks Investment Research downgraded TG Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, January 30th. Finally, ValuEngine downgraded TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, February 28th. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $14.07.

NASDAQ TGTX opened at $8.32 on Thursday. The company has a market cap of $727.52 million, a PE ratio of -4.36 and a beta of 2.31. TG Therapeutics has a one year low of $3.32 and a one year high of $16.00.

Institutional investors have recently made changes to their positions in the company. Deutsche Bank AG boosted its holdings in TG Therapeutics by 72.2% in the fourth quarter. Deutsche Bank AG now owns 824,164 shares of the biopharmaceutical company’s stock worth $3,378,000 after acquiring an additional 345,477 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of TG Therapeutics by 10.3% during the fourth quarter. Geode Capital Management LLC now owns 755,205 shares of the biopharmaceutical company’s stock worth $3,096,000 after purchasing an additional 70,398 shares during the period. Dimensional Fund Advisors LP lifted its holdings in shares of TG Therapeutics by 10.6% during the fourth quarter. Dimensional Fund Advisors LP now owns 71,312 shares of the biopharmaceutical company’s stock worth $292,000 after purchasing an additional 6,812 shares during the period. Great Point Partners LLC lifted its holdings in shares of TG Therapeutics by 53.8% during the fourth quarter. Great Point Partners LLC now owns 3,000,000 shares of the biopharmaceutical company’s stock worth $12,300,000 after purchasing an additional 1,050,000 shares during the period. Finally, Opaleye Management Inc. lifted its holdings in shares of TG Therapeutics by 57.1% during the fourth quarter. Opaleye Management Inc. now owns 550,000 shares of the biopharmaceutical company’s stock worth $2,255,000 after purchasing an additional 200,000 shares during the period. Hedge funds and other institutional investors own 55.59% of the company’s stock.

About TG Therapeutics

TG Therapeutics, Inc, a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases in the United States. It develops TG-1101 (ublituximab), a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory chronic lymphocytic leukemia.

Featured Article: Understanding Price to Earnings Ratio (PE)

Earnings History and Estimates for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Comparing Anaplan  & Its Rivals
Comparing Anaplan & Its Rivals
Head to Head Review: Twenty-First Century Fox  & TEGNA
Head to Head Review: Twenty-First Century Fox & TEGNA
Critical Comparison: Docusign  and Its Rivals
Critical Comparison: Docusign and Its Rivals
Principal Financial Group Inc. Cuts Position in Blackstone Mortgage Trust Inc
Principal Financial Group Inc. Cuts Position in Blackstone Mortgage Trust Inc
Insmed Incorporated  Shares Sold by Principal Financial Group Inc.
Insmed Incorporated Shares Sold by Principal Financial Group Inc.
Kelly Lawrence W & Associates Inc. CA Has $174,000 Position in United Technologies Co.
Kelly Lawrence W & Associates Inc. CA Has $174,000 Position in United Technologies Co.


© 2006-2019 Ticker Report